Pair page
Matrixyl with Pal-GHK
Mechanism-tag overlap and published literature for Matrixyl and Pal-GHK, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
collagen-signal-peptide
cosmetic-peptide
palmitoylated-copper-peptide-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Matrixyl and Pal-GHK have published these mechanism-level observations. Not a co-administration recommendation.
Palmitoylated form of the endogenous GHK tripeptide — the collagen-stimulating and copper-binding component of Matrixyl 3000. When Matrixyl 3000 is being used, Pal-GHK is already present as one of the two active components (along with Pal-GQPR / Palmitoyl Tetrapeptide-7). Pal-GHK's matrikine signaling is complementary to KTTKS's procollagen-propeptide signaling.
Quick facts
Matrixyl
Pal-GHK
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2009 | Matrixyl | Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. PMID: 19570099. (UCSF Dermatology systematic review of topical peptides for aged skin, including Pal-KTTKS signal-peptide class.) PMID 19570099 | systematic review |
| 2010 | Matrixyl | Fu JJ, Hillebrand GG, Raleigh P, Li J, Marmor MJ, Bertucci V, Grimes PE, Mandy SH, Perez MI, Weinkle SH, Kaczvinsky JR. A randomized, controlled comparative study of the wrinkle reduction benefits of a cosmetic niacinamide/peptide/retinyl propionate product regimen vs. a prescri… PMID 20374604 | human trial |
| 2024 | Matrixyl | Vitali A, Paolicelli P, Bigi B, Trilli J, Di Muzio L, Carriero VC, Casadei MA, Petralito S. Liposome Encapsulation of the Palmitoyl-KTTKS Peptide: Structural and Functional Characterization. Pharmaceutics. 2024;16(2):219. PMID: 38399273. (Liposomal delivery system for Pal-KTTKS… PMID 38399273 | preclinical, in vitro |
| 2017 | Matrixyl | Park H, An E, Cho Lee AR. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. Tissue Eng Regen Med. 2017;14(1):73-80. PMID: 30603464. (CTGF / α-SMA modulation and fibrobl… PMID 30603464 | preclinical, in vitro |
| 2014 | Matrixyl | Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014;22(4):321-327. PMID: 25143811. (Demonstrates palmitoylation as stability and permeation enhancer relative to un… PMID 25143811 | preclinical, in vitro |
| 2013 | Matrixyl | Jones RR, Castelletto V, Connon CJ, Hamley IW. Collagen stimulating effect of peptide amphiphile C16-KTTKS on human fibroblasts. Mol Pharm. 2013;10(3):1063-1069. PMID: 23320752. (Direct fibroblast collagen-production dose-response for Pal-KTTKS linked to critical-aggregation-con… PMID 23320752 | preclinical, in vitro |
| 2019 | Matrixyl | Tałałaj U, Uscinowicz P, Bruzgo I, Surazynski A, Zareba I, Markowska A. The Effects of a Novel Series of KTTKS Analogues on Cytotoxicity and Proteolytic Activity. Molecules. 2019;24(20):3698. PMID: 31618846. (Structure-activity series of KTTKS analogues with acetyl / lipoyl / pa… PMID 31618846 | mechanism / discovery |
| 2019 | Matrixyl | Mortazavi SM, Kobarfard F, Maibach HI, Moghimi HR. Effect of Palmitic Acid Conjugation on Physicochemical Properties of Peptide KTTKS: A Preformulation Study. J Cosmet Sci. 2019;70(6):299-312. PMID: 31829923. (Physicochemical characterization of palmitoyl conjugation effects on… PMID 31829923 | mechanism / discovery |
| 2007 | Matrixyl | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Updated Dermatologic Therapy review of signal, neurotransmitter-affecting, and carrier peptides.) PMID 18045359 | review |
| 2005 | Matrixyl | Osborne R, Mullins L, Jarrold B, Lintner K. In vitro skin structure benefits with a new antiaging peptide, Pal-KT. J Am Acad Dermatol. 2005;52(3 Suppl):P34. (AAD-meeting abstract on Pal-KT / Pal-KTTKS cosmetic evaluation; Procter & Gamble / Sederma collaboration.) | industry documentation |
| 2009 | Matrixyl | Trookman NS, Rizer RL, Ford R, Ho E, Gotz V. Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles. J Clin Aesthet Dermatol. 2009;2(3):38-43. PMID: 20729942. (8-week topical treatment clinical study including palmitoyl pentapeptide active… PMID 20729942 | research article |
| 2005 | Matrixyl | Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The 93-subject 12-week split-face vehicle-controlled RCT of 3 ppm Pa… PMID 18492182 | research article |
| 1998 | Pal-GHK | Abdulghani AA, Sherr A, Shirin S, Solodkina G, Tapia EM, Wolf B, Gottlieb AB. Effects of topical creams containing vitamin C, a copper-binding peptide cream, and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastruct… | human pilot |
| 1988 | Pal-GHK | Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID: 3138181. (Th… PMID 3138181 | preclinical, in vitro |
| 2018 | Pal-GHK | Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520; PMC6073405. (2018 gene-expression-based review using Broad… PMID 29986520 | mechanism / discovery |
| 2017 | Pal-GHK | Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences. 2017;7(2):20. doi:10.3390/brainsci7020020. PMID: 28241430. (Extension of GHK transcriptomic effects; rele… PMID 28241430 | mechanism / discovery |
| 2018 | Pal-GHK | Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029. (Contemporary MDPI Cosmetics review of copper-peptide skin biology applicable to the Pal-GHK-in-situ-GHK-Cu formation hypothesis.) | review |
| 2015 | Pal-GHK | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730; PMC4508379. (Comprehensive review of GHK's multi-pathway s… PMID 26236730 | review |
| 2008 | Pal-GHK | Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225. (Foundational review of the parent tripeptide GHK, its tissue-remodeling biology, and the copper-coor… PMID 18644225 | review |
| 2005 | Pal-GHK | Finkley MB, Appa Y, Bhandarkar S. Copper peptide and skin. Cosmeceuticals and Active Cosmetics: Drugs vs. Cosmetics. Marcel Dekker, New York; 2005:549–563. (Classical cosmetic-dermatology chapter summarizing GHK-Cu-containing facial cream clinical data — the cream data most ofte… | review |
| 2003 | Pal-GHK | Sederma (Croda International). Matrixyl 3000 technical dossier and product information sheets. Sederma, Le Perray-en-Yvelines, France. 2003–2024. (Manufacturer's technical documentation for the Pal-GHK + Pal-GQPR combination active — the primary source for recommended use levels… | industry documentation |
| 2002 | Pal-GHK | Mas-Chamberlin C, Lintner K, Basset L, Adhoute H, Revuz J. Relevance of antiwrinkle treatment of a peptide: 4 months clinical double blind study vs excipient. Annales de Dermatologie et de Vénéréologie. 2002;129(1S):456. Proceedings, 20th World Congress of Dermatology, Paris. (E… | industry documentation |
| 2000 | Pal-GHK | Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International Journal of Cosmetic Science. 2000;22(3):207-218. doi:10.1046/j.1467-2494.2000.00010.x. (Sederma researcher review of the palmitoyl-peptide lipi… | industry documentation |
| 2014 | Pal-GHK | Ricard-Blum S, Salza R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Experimental Dermatology. 2014;23(7):457-463. doi:10.1111/exd.12435. PMID: 24815015. (Modern framework paper defining the matrikine / matricryptin class to which GHK… PMID 24815015 | research article |
Related pair pages
More research context
Frequently asked
Have Matrixyl and Pal-GHK been studied together?
Researchers have published mechanistic-level co-administration discussion of Matrixyl and Pal-GHK. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Matrixyl and Pal-GHK share?
Matrixyl and Pal-GHK share these mechanism tags on their Kalios profiles: cosmetic-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Matrixyl and Pal-GHK?
Matrixyl: Cosmetic ingredient (not a drug). Pal-GHK: Cosmetic ingredient. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Matrixyl and Pal-GHK?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Matrixyl profile and the Pal-GHK profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026